Foscarnet-induced electrolyte abnormalities in a bone marrow transplant patient receiving parenteral nutrition.
Cytomegalovirus (CMV) is a serious complication of immunosuppressed patients receiving bone marrow transplantation. Foscarnet, a pyrophosphate analog, has been used in the treatment of CMV infections. Renal impairment and electrolyte abnormalities are potential adverse reactions associated with the use of foscarnet. We report a case of significant electrolyte changes after initiation of foscarnet in a bone marrow transplant patient receiving parenteral nutrition.
Matarese
L E
LE
Department of General Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA.
Speerhas
R
R
Seidner
D L
DL
Steiger
E
E
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D016026:Bone Marrow Transplantation; D003587:Cytomegalovirus / Q000187:drug effects; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000517:prevention & control; D004573:Electrolytes / Q000097:blood*; D017245:Foscarnet / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D008297:Male; D010289:Parenteral Nutrition, Total / Q000009:adverse effects*
D000998:Antiviral Agents; D004573:Electrolytes; D017245:Foscarnet